外泌体诊断和治疗市场 - 全球产业规模、份额、趋势、机会和预测，按产品、应用、来源、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球外泌体诊断和治疗市场价值为 3,321 万美元，预计到 2030 年将达到 11.7376 亿美元，复合年增长率为 81.13%。外泌体是一种小型细胞外囊泡，在细胞间通讯中发挥至关重要的作用，因其在非侵入性疾病检测和靶向药物传输方面的潜力而备受关注。市场受到癌症、神经退化性疾病和心血管疾病等慢性疾病盛行率上升的推动，其中外泌体是早期诊断和个人化治疗策略的宝贵生物标记。液体活检领域的不断扩大进一步推动了需求，因为基于外泌体的测试在早期检测疾病方面具有更高的敏感性和特异性。外泌体分离、纯化和表征技术的不断进步增强了研究能力，从而导致生物技术和製药公司对开发基于外泌体的疗法的投资增加。

市场概况
预测期	2026-2030
2024 年市场规模	3,321万美元
2030 年市场规模	11.7376亿美元
2025-2030 年复合年增长率	81.13％
成长最快的领域	干细胞
最大的市场	北美洲

人们对精准医疗和再生医学的兴趣日益浓厚，进一步促进了市场扩张。人们正在探索基于外泌体的药物传输系统，以提高效率和减少副作用的能力。人们对肿瘤学标靶治疗的日益关注，引发了对外泌体作为抗癌药物和基因治疗载体的大量研究。对于致力于实现外泌体疗法商业化的公司来说，开发大规模外泌体生产和表征的标准化协议仍然是一个关注的关键领域。儘管取得了这些进展，市场仍面临着许多挑战，例如与外泌体分离和纯化相关的高成本，以及需要获得监管部门的批准以确保外泌体衍生产品的安全性和有效性。围绕外泌体在人类治疗中的应用的伦理问题也带来了可能影响市场成长的监管障碍。

下一代定序、流式细胞仪和奈米粒子追踪分析的技术创新正在提高外泌体研究的准确性和效率，为新产品开发创造了机会。人工智慧和机器学习在外泌体资料分析中的出现进一步提高了解释复杂外泌体谱以进行疾病诊断的能力。研究机构、生技公司和製药公司之间的策略合作正在加速创新的步伐，从而发现新的外泌体应用。评估外泌体疗法的临床试验数量不断增加，凸显了未来个人化医疗突破的潜力。克服标准化和可扩展性的挑战是释放外泌体在诊断和治疗领域的全部潜力的关键，为现代医疗保健的变革性影响铺平道路。

主要市场驱动因素

慢性和危及生命的疾病发生率不断上升

外泌体分离与鑑定技术的进展

增加对外泌体研发的投资

此外，具体项目获得了大量资金；其中一个重点关注「慢性阻塞性肺病中的致病性外泌体」的计画于 2023 年获得了超过 100 万美元的资助。

另一个名为「识别基于外泌体的病变形成和 MS 的生物标记」的计画同年获得了 209,375 美元。

主要市场挑战

复杂且昂贵的外泌体分离与纯化过程

外泌体表征和品质控制缺乏标准化

主要市场趋势

基于外泌体的液体活检在癌症诊断中的应用日益广泛

人们对基于外泌体的神经系统疾病治疗的兴趣日益浓厚

分段洞察

产品洞察

应用程式洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球外泌体诊断与治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品（仪器、试剂及试剂盒、软体）
  • 按应用（诊断、治疗）
  • 依来源（干细胞、血液和血浆、尿液、其他）
  • 按最终使用者（癌症研究所、医院、诊断中心等）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第 6 章：北美外泌体诊断与治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 7 章：欧洲外泌体诊断与治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太外泌体诊断与治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲外泌体诊断与治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲外泌体诊断与治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Thermo Fisher Scientific Inc.
• Exosome Diagnostics, Inc.
• Miltenyi Biotec BV & Co. KG
• Lonza Group AG
• System Biosciences, LLC
• Hansa Biopharma AB
• Bio-Techne Corporation
• Redcell Biotechnology Inc.
• Capricor Therapeutics, Inc.
• Evox Therapeutics Limited

第 15 章：策略建议

第16章 调査会社について・免责事项

Global Exosome Diagnostic and Therapeutic Market was valued at USD 33.21 Million in 2024 and is expected to reach USD 1173.76 Million in the forecast period with a CAGR of 81.13% through 2030. The Global Exosome Diagnostic and Therapeutic Market is experiencing rapid growth due to the increasing adoption of exosome-based technologies in diagnostics and therapeutics. Exosomes, small extracellular vesicles, play a crucial role in cell-to-cell communication and have gained significant attention for their potential in non-invasive disease detection and targeted drug delivery. The market is being driven by the rising prevalence of chronic diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases, where exosomes serve as valuable biomarkers for early diagnosis and personalized treatment strategies. The expanding field of liquid biopsy is further propelling demand, as exosome-based tests offer higher sensitivity and specificity in detecting diseases at an early stage. Continuous advancements in exosome isolation, purification, and characterization techniques are enhancing research capabilities, leading to increased investment from biotechnology and pharmaceutical companies in developing exosome-based therapies.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 33.21 Million
Market Size 2030	USD 1173.76 Million
CAGR 2025-2030	81.13%
Fastest Growing Segment	Stem Cells
Largest Market	North America

Growing interest in precision medicine and regenerative medicine is further contributing to market expansion. Exosome-based drug delivery systems are being explored for their ability to transport therapeutic molecules with improved efficiency and minimal side effects. The increasing focus on targeted therapies in oncology has led to significant research on exosomes as carriers for anticancer drugs and gene therapies. The development of standardized protocols for large-scale exosome production and characterization remains a critical area of focus for companies aiming to commercialize exosome-based therapeutics. Despite these advancements, the market faces challenges such as high costs associated with exosome isolation and purification, as well as the need for regulatory approvals that ensure the safety and efficacy of exosome-derived products. Ethical concerns surrounding the use of exosomes in human therapies also pose regulatory hurdles that may impact market growth.

Technological innovations in next-generation sequencing, flow cytometry, and nanoparticle tracking analysis are enhancing the accuracy and efficiency of exosome research, creating opportunities for new product development. The emergence of artificial intelligence and machine learning in exosome data analysis is further improving the ability to interpret complex exosome profiles for disease diagnostics. Strategic collaborations between research institutions, biotech firms, and pharmaceutical companies are accelerating the pace of innovation, leading to the discovery of novel exosome applications. The increasing number of clinical trials evaluating exosome-based therapeutics highlights the potential for future breakthroughs in personalized medicine. Overcoming standardization and scalability challenges will be key to unlocking the full potential of exosomes in diagnostics and therapeutics, paving the way for a transformative impact on modern healthcare.

Key Market Drivers

Growing Prevalence of Chronic and Life-Threatening Diseases

The escalating prevalence of chronic and life-threatening diseases is a significant driver for the Global Exosome Diagnostic and Therapeutic Market, as the demand for non-invasive diagnostic tools and targeted therapies continues to rise. Exosome-based diagnostics and therapeutics are gaining traction in managing conditions such as cancer, neurodegenerative disorders, cardiovascular diseases, and autoimmune disorders, where early detection and effective treatment are crucial for improving patient outcomes.

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum, and prostate cancers. This increasing burden of cancer has created a strong need for advanced liquid biopsy techniques that utilize exosomes for tumor biomarker detection, disease progression monitoring, and treatment response assessment. Exosome-based liquid biopsies offer significant advantages over traditional tissue biopsies by enabling real-time disease monitoring with minimal patient discomfort, leading to their growing adoption in oncology.

The rising incidence of neurodegenerative diseases further fuels interest in exosome-based diagnostics and therapeutics. A major study released by The Lancet Neurology in 2024 indicates that more than 3 billion people worldwide were living with a neurological condition in 2021, highlighting the substantial global burden of these disorders. Exosomes play a crucial role in intercellular communication within the nervous system, making them valuable for early diagnosis, biomarker discovery, and targeted drug delivery in neurological disorders.

Cardiovascular diseases remain a leading cause of mortality globally, driving the need for biomarker-based diagnostics and regenerative therapies that leverage exosomes for tissue repair and inflammation modulation. Autoimmune disorders, including rheumatoid arthritis and multiple sclerosis, have also become key areas where exosome-based therapies are being explored for immune system regulation and disease modification. Increasing research efforts and clinical trials focused on exosome-based interventions have expanded their potential applications across various disease areas. The continuous rise in chronic and life-threatening conditions has intensified the need for innovative, efficient, and personalized healthcare solutions, positioning exosome diagnostics and therapeutics as transformative tools in modern medicine.

Advancements in Exosome Isolation and Characterization Technologies

Advancements in exosome isolation and characterization technologies are driving the growth of the Global Exosome Diagnostic and Therapeutic Market by enabling more precise, scalable, and efficient utilization of exosomes in diagnostics and therapeutics. Traditional isolation methods, such as ultracentrifugation, often suffer from low purity, poor yield, and labor-intensive protocols, limiting their clinical and commercial applications. The introduction of novel isolation techniques, including size-exclusion chromatography, immunoaffinity capture, microfluidic-based separation, and tangential flow filtration, has significantly improved the ability to obtain high-quality exosomes with minimal contamination. These advanced methods enhance reproducibility and enable researchers to extract exosomes with greater specificity, paving the way for their widespread use in biomarker discovery, liquid biopsy, and targeted drug delivery.

The development of high-throughput and automated exosome isolation platforms has further accelerated research and clinical translation. Companies are investing in microfluidic technologies and lab-on-a-chip systems, which allow rapid and cost-effective isolation of exosomes from various biological fluids such as blood, urine, and saliva. These advancements are critical for real-time disease monitoring, particularly in oncology, where exosome-based liquid biopsy is revolutionizing early cancer detection and treatment response assessment.

Characterization technologies have also evolved, leading to improved exosome profiling, cargo analysis, and functional validation. Innovations in nanoparticle tracking analysis (NTA), dynamic light scattering (DLS), and flow cytometry have enhanced the ability to study exosome size distribution, concentration, and surface marker expression. Advanced single-vesicle analysis techniques, Raman spectroscopy, and next-generation sequencing (NGS) are further refining exosome-based diagnostics by enabling comprehensive molecular profiling. These technological advancements are expanding exosome applications in neurology, cardiology, and immunotherapy, fostering new therapeutic strategies. With ongoing innovations in isolation and characterization methods, exosome-based products are becoming more clinically viable, positioning them as a transformative tool in personalized medicine and targeted therapeutics.

Increasing Investment in Exosome Research and Development

Increasing investment in exosome research and development is a key driver propelling the growth of the Global Exosome Diagnostic and Therapeutic Market. Governments, biotech companies, and pharmaceutical firms are allocating substantial funding to advance exosome-based diagnostics and therapeutics, recognizing their potential in precision medicine, regenerative therapy, and targeted drug delivery. The surge in funding has accelerated clinical trials, leading to the development of novel exosome-based products for applications in oncology, neurology, and cardiovascular diseases. Public and private sector collaboration has fostered innovation, resulting in advanced exosome isolation, purification, and characterization technologies that enhance the accuracy and efficiency of exosome-based applications.

In 2023, the National Institutes of Health (NIH) continued to support exosome research through various funding opportunities. For instance, the NIH issued a Notice of Special Interest (NOSI) titled "RNA Delivery Technologies for Therapeutic Applications," aiming to advance non-viral technologies for RNA-based therapeutics, including exosome-based delivery systems.

Additionally, specific projects received significant funding; one such project focused on "Pathogenic Exosomes in COPD" was granted over USD 1 million in 2023.

Another project titled "Identifying exosome-based biomarkers for lesion formation and MS" received USD 209,375 in the same year.

Venture capital investments have increased significantly, supporting the expansion of biotech startups focused on exosome-derived biomarkers, drug carriers, and regenerative medicine solutions. Pharmaceutical companies are entering strategic partnerships with research institutions to explore the clinical utility of exosomes in disease diagnostics and therapeutics.

Regulatory agencies such as the FDA and EMA are providing guidance for the standardization and approval of exosome-based products, encouraging further investment in this emerging field. The integration of artificial intelligence and bioinformatics into exosome research has gained attention, leading to the discovery of novel disease-specific biomarkers and the optimization of exosome-based drug delivery systems. With increasing investment in product development, technological advancements, and regulatory approvals, the market is poised for rapid expansion. The growing recognition of exosomes as a valuable tool in non-invasive diagnostics and targeted therapeutics continues to attract investors, driving innovations that enhance patient outcomes and transform modern healthcare.

Key Market Challenges

Complex and Costly Exosome Isolation and Purification Processes

The complex and costly nature of exosome isolation and purification remains a significant challenge in the Global Exosome Diagnostic and Therapeutic Market. Exosome-based applications rely on high-purity exosome samples, requiring advanced isolation techniques that are both labor-intensive and expensive. Current methods, such as ultracentrifugation, size-exclusion chromatography, polymer-based precipitation, and immunoaffinity capture, often involve multiple steps, specialized equipment, and skilled personnel, increasing operational costs. Many of these techniques yield low exosome recovery rates, contamination with non-exosomal vesicles, and batch-to-batch variability, impacting reproducibility and scalability in clinical and commercial settings.

The transition from research-based applications to clinical and industrial-scale production remains a hurdle due to the lack of standardized, high-throughput isolation technologies. Automated systems capable of processing large sample volumes while maintaining purity and functionality are still under development. The use of microfluidics and novel nanotechnology-based platforms shows promise, but their high initial investment costs limit widespread adoption. Regulatory concerns further complicate the issue, as ensuring the purity, potency, and safety of isolated exosomes requires stringent quality control measures, contributing to increased manufacturing expenses.

High production costs directly affect the affordability of exosome-based diagnostics and therapeutics, limiting accessibility, particularly in developing markets. Companies are actively exploring cost-effective, scalable alternatives, yet the absence of universally accepted isolation protocols continues to slow clinical translation. Addressing this challenge requires advancements in automation, process optimization, and regulatory harmonization to support the widespread adoption of exosome-based products in healthcare.

Lack of Standardization in Exosome Characterization and Quality Control

Lack of standardization in exosome characterization and quality control presents a significant challenge in the Global Exosome Diagnostic and Therapeutic Market. Exosomes are heterogeneous in nature, varying in size, composition, and biological function depending on their cellular origin and isolation method. The absence of universally accepted protocols for exosome isolation, purification, and characterization leads to inconsistencies in research outcomes, making it difficult to compare data across studies and develop reliable clinical applications. Different techniques such as ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture yield exosomes with varying purity and biomolecular content, affecting their diagnostic and therapeutic efficacy. The lack of reproducibility in exosome isolation impacts their biomarker potential, drug delivery capabilities, and regenerative medicine applications, limiting widespread clinical adoption.

Regulatory challenges further complicate standardization efforts. Agencies such as the FDA and EMA have yet to establish clear guidelines on the classification, safety, and efficacy requirements for exosome-based products. The complexity of exosome composition, including proteins, nucleic acids, and lipids, requires rigorous quality control measures to ensure batch-to-batch consistency in therapeutic applications. Variability in storage and handling conditions also affects exosome stability, reducing their shelf life and impacting their functional properties. The absence of standardized exosome reference materials and validated analytical methods makes regulatory approval processes lengthy and uncertain. Without clear quality control frameworks, pharmaceutical companies and diagnostic firms face hurdles in achieving large-scale manufacturing and commercialization of exosome-based products. The development of standardized protocols, consensus guidelines, and advanced analytical technologies is essential to overcoming these challenges, ensuring exosome-based diagnostics and therapeutics achieve clinical reliability and regulatory approval for widespread use in precision medicine.

Key Market Trends

Increasing Adoption of Exosome-Based Liquid Biopsy in Cancer Diagnostics

The increasing adoption of exosome-based liquid biopsy in cancer diagnostics is transforming the landscape of non-invasive disease detection and monitoring. Exosomes, as nanosized extracellular vesicles, carry valuable biomolecules such as RNA, DNA, proteins, and lipids, making them powerful tools for identifying cancer-specific biomarkers. Traditional tissue biopsy methods are invasive, often painful, and may not always capture the heterogeneity of tumors. Liquid biopsy using exosomes offers a minimally invasive alternative by enabling the detection of tumor-derived exosomes in bodily fluids like blood, urine, and saliva. This method allows for real-time monitoring of disease progression, early detection of malignancies, and assessment of treatment responses.

The growing burden of cancer worldwide, coupled with the need for early-stage detection, has fueled the demand for more accurate and efficient diagnostic solutions. Exosome-based liquid biopsy provides a higher level of sensitivity and specificity compared to circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), as exosomes protect their cargo from enzymatic degradation, ensuring reliable biomarker detection. Research has demonstrated the potential of exosome-derived microRNAs (miRNAs) and proteins as predictive biomarkers for various cancers, including lung, breast, pancreatic, and prostate cancer. The application of next-generation sequencing (NGS), artificial intelligence (AI), and machine learning in exosome biomarker analysis has further enhanced diagnostic accuracy, enabling personalized treatment strategies.

Pharmaceutical and biotechnology companies are heavily investing in exosome-based liquid biopsy platforms, leading to the development of commercially available diagnostic assays. The rise in clinical trials, regulatory approvals, and strategic collaborations among biotech firms and research institutions has accelerated the adoption of this innovative approach. With continuous advancements in exosome isolation techniques, bioinformatics integration, and point-of-care testing technologies, liquid biopsy is expected to become a mainstream diagnostic tool for cancer detection, significantly improving patient outcomes and reducing healthcare costs.

Rising Interest in Exosome-Based Therapeutics for Neurological Disorders

The increasing interest in exosome-based therapeutics for neurological disorders is significantly influencing the Global Exosome Diagnostic and Therapeutic Market. Exosomes, as extracellular vesicles secreted by various cell types, have been recognized for their role in intercellular communication within the nervous system. Their unique ability to cross the blood-brain barrier (BBB) allows them to deliver therapeutic agents directly to affected neurons, making them promising candidates for treating neurological conditions such as Alzheimer's disease, Parkinson's disease, and stroke.

Recent studies have highlighted the potential of exosomes to carry neuroprotective agents, including proteins, RNAs, and small molecules, which can modulate disease progression and promote neural regeneration. For instance, exosomes derived from mesenchymal stem cells (MSCs) have demonstrated anti-inflammatory and neuroprotective effects in preclinical models, suggesting their utility in mitigating neuroinflammation and supporting neural repair mechanisms. The therapeutic application of exosomes is further supported by their low immunogenicity and natural origin, which offer advantages over synthetic drug delivery systems. As research advances, the development of engineered exosomes with enhanced targeting capabilities and optimized cargo loading is expected to drive the growth of exosome-based therapies in the neurological field. The integration of exosome-based approaches into clinical practice holds the potential to revolutionize the treatment landscape for neurological disorders, addressing unmet medical needs and improving patient outcomes.

Segmental Insights

Product Insights

Based on the Product, Reagents and Kits emerged as the dominant segment in the Global Exosome Diagnostic and Therapeutic Market in 2024. This is due to their essential role in exosome isolation, purification, characterization, and analysis across research and clinical applications. The increasing adoption of exosome-based diagnostics, particularly in liquid biopsy for cancer detection and disease monitoring, has driven the demand for standardized, high-quality reagents and kits that enable reliable and reproducible results. Researchers and biotech companies require efficient exosome isolation methods, and ready-to-use kits offer simplified workflows, high specificity, and faster processing times, making them indispensable in laboratories. Furthermore, the rise in funding for exosome research, expanding applications in personalized medicine, and increasing clinical trials for exosome-based therapeutics have significantly boosted the demand for specialized reagents, including exosome-specific antibodies, RNA extraction kits, and labeling reagents. The growing interest in drug delivery and regenerative medicine has also contributed to the segment's dominance, as cargo loading rely on advanced reagents for modification and functionalization. With ongoing advancements in next-generation isolation technologies and automation, coupled with the widespread use of exosome-based research tools, the reagents and kits segment is expected to maintain its leadership position in the market, supporting the expansion of exosome-based diagnostics and therapeutics.

Application Insights

Based on the Application, Diagnostic emerged as the dominant segment in the Global Exosome Diagnostic and Therapeutic Market in 2024. This is due to the rising adoption of exosome-based liquid biopsy for early disease detection and monitoring. Exosomes contain a wealth of biomarkers, including RNA, DNA, and proteins, which provide critical insights into various diseases, particularly cancer, neurodegenerative disorders, and cardiovascular conditions. The increasing burden of cancer worldwide has driven the demand for non-invasive diagnostic solutions, with exosome-based liquid biopsy offering a superior alternative to traditional tissue biopsies by enabling real-time disease monitoring, early-stage detection, and treatment response assessment. Additionally, exosome-based diagnostics are gaining traction in neurological disorders such as Alzheimer's and Parkinson's disease, where they facilitate early diagnosis and disease progression tracking. The growing investment in precision medicine, advancements in next-generation sequencing (NGS) and artificial intelligence (AI) in biomarker discovery, and increasing clinical trials for exosome-based diagnostic assays have further propelled the segment's growth. The rising availability of exosome isolation and characterization kits, along with improved standardization of exosome biomarkers, has accelerated clinical adoption. As healthcare providers and researchers continue to explore new applications for exosome diagnostics, this segment is expected to maintain its dominance, revolutionizing disease detection and personalized healthcare approaches.

Regional Insights

North America emerged as the dominant region in the Global Exosome Diagnostic and Therapeutic Market in 2024. This is due to its strong biotechnology and pharmaceutical infrastructure, high research funding, and early adoption of advanced diagnostic and therapeutic technologies. The United States has been at the forefront of exosome-based research and commercialization, driven by the increasing demand for liquid biopsy, precision medicine, and regenerative therapies. The region's well-established healthcare ecosystem, presence of leading biopharmaceutical companies, and extensive clinical research initiatives have contributed to market leadership. Additionally, the rising prevalence of cancer, neurodegenerative disorders, and cardiovascular diseases has fueled demand for non-invasive exosome-based diagnostics and drug delivery solutions. Government support through funding programs from the National Institutes of Health (NIH) and the Food and Drug Administration (FDA)'s expedited regulatory pathways has further accelerated the development and approval of exosome-based products. Moreover, North America has witnessed significant strategic collaborations, mergers, and acquisitions among biotech firms, academic institutions, and pharmaceutical giants to advance exosome-based therapies. The growing integration of artificial intelligence (AI) and bioinformatics in exosome biomarker discovery has also enhanced diagnostic accuracy, driving adoption. With continuous advancements in clinical research, product commercialization, and regulatory support, North America is expected to maintain its leadership position in the exosome diagnostics and therapeutics market.

Key Market Players

• Thermo Fisher Scientific Inc.
• Exosome Diagnostics, Inc.
• Miltenyi Biotec B.V. & Co. KG
• Lonza Group AG
• System Biosciences, LLC
• Hansa Biopharma AB
• Bio-Techne Corporation
• Redcell Biotechnology Inc.
• Capricor Therapeutics, Inc.
• Evox Therapeutics Limited

Report Scope:

In this report, the Global Exosome Diagnostic and Therapeutic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Exosome Diagnostic and Therapeutic Market, By Product:

• Instruments
• Reagents and Kits
• Software

Exosome Diagnostic and Therapeutic Market, By Application:

• Diagnostic
• Therapeutic

Exosome Diagnostic and Therapeutic Market, By Source:

• Stem Cells
• Blood and Blood Plasma
• Urine
• Others

Exosome Diagnostic and Therapeutic Market, By End User:

• Cancer Institutes
• Hospitals
• Diagnostic Centers
• Others

Exosome Diagnostic and Therapeutic Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Exosome Diagnostic and Therapeutic Market.

Available Customizations:

Global Exosome Diagnostic and Therapeutic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Exosome Diagnostic and Therapeutic Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Reagents and Kits, Software)
  • 5.2.2. By Application (Diagnostic, Therapeutic)
  • 5.2.3. By Source (Stem Cells, Blood and Blood Plasma, Urine, Others)
  • 5.2.4. By End User (Cancer Institutes, Hospitals, Diagnostic Centers, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Exosome Diagnostic and Therapeutic Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Source
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Exosome Diagnostic and Therapeutic Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Source
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Exosome Diagnostic and Therapeutic Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Source
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Exosome Diagnostic and Therapeutic Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Source
      • 6.3.3.2.4. By End User

7. Europe Exosome Diagnostic and Therapeutic Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Source
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Exosome Diagnostic and Therapeutic Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Source
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Exosome Diagnostic and Therapeutic Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Source
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Exosome Diagnostic and Therapeutic Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Source
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Exosome Diagnostic and Therapeutic Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Source
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Exosome Diagnostic and Therapeutic Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Source
      • 7.3.5.2.4. By End User

8. Asia-Pacific Exosome Diagnostic and Therapeutic Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Source
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Exosome Diagnostic and Therapeutic Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Source
      • 8.3.1.2.4. By End User
  • 8.3.2. India Exosome Diagnostic and Therapeutic Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Source
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Exosome Diagnostic and Therapeutic Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Source
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Exosome Diagnostic and Therapeutic Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Source
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Exosome Diagnostic and Therapeutic Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Source
      • 8.3.5.2.4. By End User

9. South America Exosome Diagnostic and Therapeutic Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Source
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Exosome Diagnostic and Therapeutic Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Source
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Exosome Diagnostic and Therapeutic Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Source
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Exosome Diagnostic and Therapeutic Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Source
      • 9.3.3.2.4. By End User

10. Middle East and Africa Exosome Diagnostic and Therapeutic Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Source
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Exosome Diagnostic and Therapeutic Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Source
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Exosome Diagnostic and Therapeutic Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Source
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Exosome Diagnostic and Therapeutic Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Source
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Exosome Diagnostics, Inc.
• 14.3. Miltenyi Biotec B.V. & Co. KG
• 14.4. Lonza Group AG
• 14.5. System Biosciences, LLC
• 14.6. Hansa Biopharma AB
• 14.7. Bio-Techne Corporation
• 14.8. Redcell Biotechnology Inc.
• 14.9. Capricor Therapeutics, Inc.
• 14.10. Evox Therapeutics Limited

15. Strategic Recommendations

16. About Us & Disclaimer